Abstract: Extract see also Chapters 6, 8, 15, 17, 20, 22, 23, 28, 29, 30, 51, 55, 110 Introduction Conventional amphotericin B deoxycholate, fluconazole, and 5-fluorocytosine (5-FC) have until recently been the mainstay of antifungal therapy in invasive fungal infection (IFI). Lipid amphotericin preparations are less toxic than conventional preparations, and along with azole antifungal agents, increase the options for treating invasive fungal diseases. With the advent of novel azoles, such as voriconazole and posaconazole, along with echinocandin drugs such as caspofungin, treatment can be tailored to the fungus species isolated and its drug sensitivity, as well as the degree of risk from immunosuppression. However, there is a paucity of high-quality data evaluating the efficacy of antifungal drugs in children, and paediatric pharmacokinetic data for the older and the newer antifungal agents are limited, making research in this field a key priority. For all drug doses, see Appendix 5. Fungal classification Yeasts:
Publication Year: 2011
Publication Date: 2011-01-01
Language: en
Type: book-chapter
Indexed In: ['crossref']
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot